Genitourinary Cancers Symposium

First-Line Pembrolizumab plus Axitinib Combination Boosts Survival in Metastatic Renal-Cell Carcinoma

Phoebe Starr

April 2019, Vol 10, No 2 - Genitourinary Cancers Symposium

San Francisco, CA—First-line therapy with pembrolizumab (Keytruda) plus ­axitinib (Inlyta) significantly improved overall survival (OS), progression-free survival (PFS), and objective response rates compared with standard-of-care sunitinib (Sutent) in patients with clear-cell metastatic renal-cell carcinoma (RCC) in KEYNOTE-426. The combination of pembrolizumab plus axitinib achieved a significant 47% reduction in mortality risk versus sunitinib (P <.0001). [ Read More ]

Real-World Outcomes Show Benefits of Immune Checkpoint Inhibitors in Patients with Kidney Cancer

Phoebe Starr

April 2017, Vol 8, No 2 - Genitourinary Cancers Symposium

Orlando, FL—Clinical trials involving immunotherapy have increased in the past few years, and the oncology community is eagerly awaiting the results. However, not so well-known is what happens to patients who receive immunotherapy outside of the clinical trial setting, including those who are not eligible for clinical trials. [ Read More ]

1 Cycle of BEP Regimen Equal to 2 Cycles in Patients with High-Risk, Stage 1 Testicular Cancer

Phoebe Starr

April 2017, Vol 8, No 2 - Genitourinary Cancers Symposium

Orlando, FL—One cycle of the bleomycin, etoposide, and cisplatin (BEP) regimen had less toxicity and was as effective as 2 cycles in patients with high-risk, nonseminomatous or germ-cell tumors of the testis (NSGCTT), according to results of a large prospective trial called 111 presented at the 2017 Genitourinary Cancers Symposium. Using 1 cycle of BEP as standard of care would reduce exposure to toxicity, and most patients with testicular cancer are relatively young. [ Read More ]

Localized Renal Cancer Surgery Associated with Substantial Costs from Lost Productivity

Phoebe Starr

March 2015, Vol 6, No 2 - Genitourinary Cancers Symposium

Orlando, FL—The total costs of renal surgery are not limited to hospitalization but accrue long after discharge. According to data presented at the 2015 Genitourinary Cancers Symposium, most patients took more than 30 days off work after radical or partial nephrectomy, with the average estimated wages lost to unpaid time exceeding $10,000. [ Read More ]

Debate on PSA Prostate Cancer Screening Redux

Phoebe Starr

March 2015, Vol 6, No 2 - Genitourinary Cancers Symposium

Orlando, FL—A new retrospective study of 87,562 men diagnosed with prostate cancer between January 2005 and June 2013 show that the incidence of prostate cancer and men with prostate-specific antigen (PSA) >10 decreased gradually between 2005 and 2011. However, the incidence of high-risk prostate cancer at diagnosis increased annually by 3% between 2011 and 2013, totaling 6%. This increase could lead to an additional 1400 prostate cancer deaths 10 years later. [ Read More ]

History of Testicular Cancer Increases Risk for Aggressive Prostate Cancer Later on

Phoebe Starr

March 2015, Vol 6, No 2 - Genitourinary Cancers Symposium

Orlando, FL—Previous studies have shown that a history of testicular cancer increases the risk for developing prostate cancer. A new study presented at the 2015 Genitourinary Cancers Symposium shows, for the first time ever, a link between a history of testicular cancer and an increased likelihood of intermediate- and high-risk prostate cancer sometime in the future. [ Read More ]

Caution: Active Surveillance Ill Advised in Men with Intermediate-Risk Prostate Cancer

Phoebe Starr

March 2015, Vol 6, No 2 - Genitourinary Cancers Symposium

Orlando, FL—Active surveillance is sometimes used as management strategy in patients with intermediate-risk prostate cancer, especially in older, sicker men with short life expectancy. A new study validates the use of active surveillance for men with low-risk prostate cancer but provides sobering data regarding this type of management for those with intermediate-risk prostate cancer. The study results were presented at the 2015 Genitourinary Cancers Symposium. [ Read More ]